<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="153882">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01096667</url>
  </required_header>
  <id_info>
    <org_study_id>8835-042</org_study_id>
    <nct_id>NCT01096667</nct_id>
  </id_info>
  <brief_title>Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)</brief_title>
  <official_title>A 4-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study To Evaluate The Safety, Tolerability And Efficacy Of Once Daily PF-04971729 And Hydrochlorothiazide In Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic And Blood Pressure Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      MK-8835-042 (B1521004) is designed to assess the safety and efficacy of an investigational
      drug, ertugliflozin (MK-8835, PF-04971729), in participants with type 2 diabetes and
      hypertension. Participants in the study will receive 1 of 5 treatments for 1 month including
      1 treatment with an approved drug - hydrochlorothiazide (HCTZ).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline on average, 24 hour systolic blood pressure (SBP) on Day 28 assessed using 24 hour ambulatory blood pressure monitoring (ABPM)</measure>
    <time_frame>Baseline and Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on average, daytime, night time, and 24-hour diastolic blood pressure (DBP) on Day 28 using 24 hour ABPM</measure>
    <time_frame>Baseline and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on average daytime, night time SBP on Day 28 using 24 hour ABPM</measure>
    <time_frame>Baseline and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in trough SBP and DBP using automated device</measure>
    <time_frame>Baseline and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on 24 hour urinary glucose excretion on Day 28</measure>
    <time_frame>Baseline and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting plasma glucose on Day 28</measure>
    <time_frame>Baseline and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in trough pulse rate on Day 28 using automated device</measure>
    <time_frame>Baseline and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on average, daytime, night time pulse rate on Day 28 using 24 hour ABPM</measure>
    <time_frame>Baseline and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who experienced and adverse event (AE)</measure>
    <time_frame>Up to 28 days postdose (Up to 56 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who discontinued study drug due to an AE</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">195</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for Ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to HCTZ, once daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ertugliflozin 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ertugliflozin 1 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ertugliflozin 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ertugliflozin 5 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ertugliflozin 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ertugliflozin 25 mg, placebo to ertugliflozin (1 mg or 5 mg), and placebo to HCTZ, once daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCTZ 12.5mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HCTZ 12.5 mg, placebo to ertugliflozin (1 mg or 5 mg and 25 mg), once daily for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Ertuglilflozin</intervention_name>
    <description>pill(s) (1 mg and/or 5 mg and/or 25 mg) once daily for 28 days</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Ertugliflozin 1 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 5 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 25 mg</arm_group_label>
    <arm_group_label>HCTZ 12.5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1 mg Ertugliflozin</intervention_name>
    <description>pill, 1 mg, once daily for 28 days</description>
    <arm_group_label>Ertugliflozin 1 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 mg Ertugliflozin</intervention_name>
    <description>pill, 5 mg, once daily for 28 days</description>
    <arm_group_label>Ertugliflozin 5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>25 mg Ertugliflozin</intervention_name>
    <description>pill, 25 mg, once daily for 28 days</description>
    <arm_group_label>Ertugliflozin 25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCTZ 12.5mg</intervention_name>
    <description>capsule, 12.5 mg, once daily for 28 days</description>
    <arm_group_label>HCTZ 12.5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to HCTZ</intervention_name>
    <description>capsule, 12.5 mg, once daily for 28 days</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Ertugliflozin 1 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 5 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 25 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with type 2 diabetes and hypertension

          -  Medically stable

          -  On at least 1 (and up to 2) oral diabetes drugs

          -  And up to 2 medicines for blood pressure control

        Exclusion Criteria:

          -  Patients with type 1 diabetes

          -  Heart attack

          -  Stroke

          -  Uncontrolled blood pressure

          -  Significant kidney disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>India</country>
    <country>Malaysia</country>
    <country>Puerto Rico</country>
    <country>Serbia</country>
    <country>Taiwan</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Amin NB, Wang X, Mitchell JR, Lee DS, Nucci G, Rusnak JM. Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension. Diabetes Obes Metab. 2015 Aug;17(8):805-8. doi: 10.1111/dom.12486. Epub 2015 Jun 17.</citation>
    <PMID>25951755</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 3, 2016</lastchanged_date>
  <firstreceived_date>March 26, 2010</firstreceived_date>
  <firstreceived_results_disposition_date>April 10, 2013</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>type 2 diabetes</keyword>
  <keyword>hypertension</keyword>
  <keyword>ambulatory blood pressure monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
